Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics Statistics

Total Valuation

DRMA has a market cap or net worth of $2.87 million. The enterprise value is -$1.79 million.

Market Cap	2.87M
Enterprise Value	-1.79M

Important Dates

The last earnings date was Friday, November 14, 2025, after market close.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

DRMA has 1.03 million shares outstanding. The number of shares has increased by 871.92% in one year.

Current Share Class	1.03M
Shares Outstanding	1.03M
Shares Change (YoY)	+871.92%
Shares Change (QoQ)	+60.95%
Owned by Insiders (%)	10.50%
Owned by Institutions (%)	1.30%
Float	828,930

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.60
P/TBV Ratio	0.73
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.56

Current Ratio	4.56
Quick Ratio	4.20
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -203.36% and return on invested capital (ROIC) is -130.35%.

Return on Equity (ROE)	-203.36%
Return on Assets (ROA)	-96.45%
Return on Invested Capital (ROIC)	-130.35%
Return on Capital Employed (ROCE)	-229.12%
Revenue Per Employee	n/a
Profits Per Employee	-$1.11M
Employee Count	8
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -77.78% in the last 52 weeks. The beta is 0.53, so DRMA's price volatility has been lower than the market average.

Beta (5Y)	0.53
52-Week Price Change	-77.78%
50-Day Moving Average	3.68
200-Day Moving Average	6.80
Relative Strength Index (RSI)	41.89
Average Volume (20 Days)	60,317

Short Selling Information

The latest short interest is 14,002, so 1.36% of the outstanding shares have been sold short.

Short Interest	14,002
Short Previous Month	31,179
Short % of Shares Out	1.36%
Short % of Float	1.69%
Short Ratio (days to cover)	0.29

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-9.07M
Pretax Income	-8.85M
Net Income	-8.85M
EBITDA	n/a
EBIT	-9.07M
Earnings Per Share (EPS)	-$12.13

Balance Sheet

The company has $4.66 million in cash and n/a in debt, giving a net cash position of $4.66 million or $4.54 per share.

Cash & Cash Equivalents	4.66M
Total Debt	n/a
Net Cash	4.66M
Net Cash Per Share	$4.54
Equity (Book Value)	3.96M
Book Value Per Share	4.69
Working Capital	3.96M

Cash Flow

Operating Cash Flow	-9.34M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

DRMA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-871.92%
Shareholder Yield	-871.92%
Earnings Yield	-307.84%
FCF Yield	n/a

Analyst Forecast

The average price target for DRMA is $10.00, which is 257.14% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$10.00
Price Target Difference	257.14%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on August 1, 2025. It was a reverse split with a ratio of 1:10.

Last Split Date	Aug 1, 2025
Split Type	Reverse
Split Ratio	1:10

Scores

Altman Z-Score	n/a
Piotroski F-Score	1